Postoperative Pain Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight

The Postoperative Pain market size was valued ~USD 2,440 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

LAS VEGAS, NEVADA, UNITED STATES, July 4, 2024 /EINPresswire.com/ -- DelveInsight’s “Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postoperative Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postoperative Pain Market Forecast

Some of the key facts of the Postoperative Pain Market Report:
The Postoperative Pain market size was valued ~USD 2,440 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

In January 2024, Heron Therapeutics announced that the FDA approved its supplemental New Drug Application (sNDA) for bupivacaine and meloxicam extended-release solution. The approval expands its indication to include soft tissue and orthopedic surgical procedures, specifically those where direct exposure to articular cartilage is avoided.

In the United States, approximately 46,990,000 cases of postoperative pain were reported in 2023. Analysts project a steady increase in these cases by 2034, driven by a respectable compound annual growth rate (CAGR).
In 2023, postoperative pain cases in the US were categorized by severity as follows: mild cases accounted for 25%, moderate cases for 45%, and severe cases for 31% of the total incidents.

In 2023, the distribution of postoperative pain severity in the US was as follows: approximately 25% of cases were classified as mild, 45% as moderate, and 31% as severe among the total incident cases.

In 2023, within the EU4 countries and the UK, Germany recorded the highest number of new cases of postoperative pain, totaling approximately 5,100,000 cases, followed by France.

In the UK, around 4,050,000 new cases of postoperative pain were reported in 2023.

Key Postoperative Pain Companies: Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others

Key Postoperative Pain Therapies: TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic^®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others

The Postoperative Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postoperative Pain pipeline products will significantly revolutionize the Postoperative Pain market dynamics.

Postoperative Pain Overview
Postoperative pain refers to pain that occurs after surgery. It is a common outcome following surgical procedures and can vary widely in intensity and duration depending on factors such as the type of surgery, individual pain tolerance, and the effectiveness of pain management strategies employed by healthcare providers.

Get a Free sample for the Postoperative Pain Market Report:\
https://www.delveinsight.com/report-store/postoperative-pain-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Postoperative Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postoperative Pain Epidemiology Segmentation:
The Postoperative Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Number of Incident Cases of Postoperative Pain in the 7MM
Total Number of Surgical Procedures(inpatient and outpatient) in the 7MM
Severity-specific Incident Cases of Postoperative Pain in the 7MM

Download the report to understand which factors are driving Postoperative Pain epidemiology trends @ Postoperative Pain Epidemiology Forecast

Postoperative Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Pain market or expected to get launched during the study period. The analysis covers Postoperative Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Postoperative Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postoperative Pain Therapies and Key Companies
TLC590: Taiwan Liposome Company (TLC)
TPU-006: Teikoku Pharma USA
CA-008: Concentric Analgesics
SVT-15473: Salvat Laboratories
VX-548: Vertex Pharmaceuticals
OCS-01: Oculis
N1539: Baudax Bio
SHR0410: Jiangsu HengRui Medicine
Ketorolac tromethamine: Darnitsa Pharma
AYX1: Adynxx, Inc.
EXPAREL: Pacira Pharma
Toragesic^®: Apsen Farmaceutica S.A.
SABER-Bupivacaine: Durect
lyrica: Pfizer
VVZ-149: Vivozon, Inc.
Tapentadol (OS): Grünenthal GmbH
Percocet: Mallinckrodt
YM177: Astellas Pharma Inc
LMX4: Ferndale Laboratories, Inc.

Postoperative Pain Market Strengths
Drugs with a novel mechanism of action would provide new treatment options to the patients. For instance, SVT-15473 is a “superpotent” corticosteroid that has never been used before as eye drops.
Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications.

Postoperative Pain Market Opportunities
Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.
Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat postoperative pain.

Scope of the Postoperative Pain Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Postoperative Pain Companies: Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Postoperative Pain Therapies: TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic^®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
Postoperative Pain Therapeutic Assessment: Postoperative Pain current marketed and Postoperative Pain emerging therapies
Postoperative Pain Market Dynamics: Postoperative Pain market drivers and Postoperative Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Postoperative Pain Unmet Needs, KOL’s views, Analyst’s views, Postoperative Pain Market Access and Reimbursement

To know more about Postoperative Pain companies working in the treatment market, visit @ Postoperative Pain Clinical Trials and Therapeutic Assessment

Table of Contents
1. Postoperative Pain Market Report Introduction
2. Executive Summary for Postoperative Pain
3. SWOT analysis of Postoperative Pain
4. Postoperative Pain Patient Share (%) Overview at a Glance
5. Postoperative Pain Market Overview at a Glance
6. Postoperative Pain Disease Background and Overview
7. Postoperative Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Postoperative Pain
9. Postoperative Pain Current Treatment and Medical Practices
10. Postoperative Pain Unmet Needs
11. Postoperative Pain Emerging Therapies
12. Postoperative Pain Market Outlook
13. Country-Wise Postoperative Pain Market Analysis (2020–2034)
14. Postoperative Pain Market Access and Reimbursement of Therapies
15. Postoperative Pain Market Drivers
16. Postoperative Pain Market Barriers
17. Postoperative Pain Appendix
18. Postoperative Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here